EWING, NJ--(Marketwire - January 29, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or "The Company") announced today that it has successfully achieved a two-year milestone in the long-term stability program of the key ingredient of RiVax™, a recombinant subunit vaccine against ricin toxin. RiVax™ is intended to protect against exposure to ricin toxin that might result from the purposeful release of ricin in an aerosolized form, or as a poisonous contaminant in food or water.
